147 related articles for article (PubMed ID: 36143189)
41. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
[TBL] [Abstract][Full Text] [Related]
42. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
Bauer K; Parise C; Caggiano V
BMC Cancer; 2010 May; 10():228. PubMed ID: 20492696
[TBL] [Abstract][Full Text] [Related]
43. Differential survival and recurrence patterns of patients operated for breast cancer according to the new immunohistochemical classification: analytical survey from 1997 to 2012.
García Fernández A; Chabrera C; García Font M; Fraile M; Gónzalez S; Barco I; González C; Cirera L; Veloso E; Lain JM; Pessarrodona A; Giménez N
Tumour Biol; 2013 Aug; 34(4):2349-55. PubMed ID: 23605321
[TBL] [Abstract][Full Text] [Related]
44. Impact of receptor phenotype on nodal burden in patients with breast cancer who have undergone neoadjuvant chemotherapy.
Boland MR; McVeigh TP; O'Flaherty N; Gullo G; Keane M; Quinn CM; McDermott EW; Lowery AJ; Kerin MJ; Prichard RS
BJS Open; 2017 Apr; 1(2):39-45. PubMed ID: 29951604
[TBL] [Abstract][Full Text] [Related]
45. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
[TBL] [Abstract][Full Text] [Related]
46. Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype.
Di Micco R; Zuber V; Fiacco E; Carriero F; Gattuso MI; Nazzaro L; Panizza P; Gianolli L; Canevari C; Di Muzio N; Pasetti M; Sassi I; Zambetti M; Gentilini OD
Eur J Surg Oncol; 2019 Jun; 45(6):969-975. PubMed ID: 30744944
[TBL] [Abstract][Full Text] [Related]
47. Additional Nodal Disease Prediction in Breast Cancer with Sentinel Lymph Node Metastasis Based on Clinicopathological Features.
Orsaria P; Caredda E; Genova F; Materazzo M; Capuano I; Vanni G; Granai AV; DE Majo A; Portarena I; Sileri P; Petrella G; Palombi L; Buonomo OC
Anticancer Res; 2018 Apr; 38(4):2109-2117. PubMed ID: 29599329
[TBL] [Abstract][Full Text] [Related]
48. Breast cancer molecular subtype as a predictor of the utility of preoperative MRI.
Ha R; Jin B; Mango V; Friedlander L; Miloshev V; Malak S; Wynn R
AJR Am J Roentgenol; 2015 Jun; 204(6):1354-60. PubMed ID: 26001248
[TBL] [Abstract][Full Text] [Related]
49. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
[TBL] [Abstract][Full Text] [Related]
50. Clinicopathologic subtypes and compromise of lymph nodes in patients with breast cancer.
Jaime Jans B; Nicolás Escudero M; Dahiana Pulgar B; Francisco Acevedo C; César Sánchez R; Camus AM
Ecancermedicalscience; 2014; 8():448. PubMed ID: 25114720
[TBL] [Abstract][Full Text] [Related]
51. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement.
Ugras S; Stempel M; Patil S; Morrow M
Ann Surg Oncol; 2014 Nov; 21(12):3780-6. PubMed ID: 24952028
[TBL] [Abstract][Full Text] [Related]
52. Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer?
Jones T; Neboori H; Wu H; Yang Q; Haffty BG; Evans S; Higgins S; Moran MS
Ann Surg Oncol; 2013 Sep; 20(9):2866-72. PubMed ID: 23661183
[TBL] [Abstract][Full Text] [Related]
53. Predictive factors of isolated tumor cells and micrometastases in axillary lymph nodes in breast cancer.
Madsen EV; Elias SG; van Dalen T; van Oort PM; van Gorp J; Gobardhan PD; Bongers V
Breast; 2013 Oct; 22(5):748-52. PubMed ID: 23313060
[TBL] [Abstract][Full Text] [Related]
54. Breast cancer molecular subtypes and receptor status among women at Potchefstroom Hospital: a cross-sectional study.
Kakudji BK; Mwila PK; Burger JR; du Plessis JM; Naidu K
Pan Afr Med J; 2021; 38():85. PubMed ID: 33889251
[TBL] [Abstract][Full Text] [Related]
55. Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer.
Xiao Y; Zhang S; Hou G; Zhang X; Hao X; Zhang J
Tumour Biol; 2014 Mar; 35(3):2035-45. PubMed ID: 24096546
[TBL] [Abstract][Full Text] [Related]
56. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
Ruano R; Ramos M; García-Talavera JR; Ramos T; Rosero AS; González-Orus JM; Sancho M
Rev Esp Med Nucl Imagen Mol; 2014; 33(6):340-5. PubMed ID: 24856234
[TBL] [Abstract][Full Text] [Related]
57. Axillary ultrasound for preoperative nodal staging in breast cancer patients: is it of added value?
Schipper RJ; van Roozendaal LM; de Vries B; Pijnappel RM; Beets-Tan RG; Lobbes MB; Smidt ML
Breast; 2013 Dec; 22(6):1108-13. PubMed ID: 24095611
[TBL] [Abstract][Full Text] [Related]
58. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Iorfida M; Mazza M; Balduzzi A; Veronesi P; Luini A; Intra M; Goldhirsch A; Colleoni M
Ann Oncol; 2013 Mar; 24(3):661-8. PubMed ID: 23022996
[TBL] [Abstract][Full Text] [Related]
59. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
60. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
Fountzilas G; Dafni U; Bobos M; Batistatou A; Kotoula V; Trihia H; Malamou-Mitsi V; Miliaras S; Chrisafi S; Papadopoulos S; Sotiropoulou M; Filippidis T; Gogas H; Koletsa T; Bafaloukos D; Televantou D; Kalogeras KT; Pectasides D; Skarlos DV; Koutras A; Dimopoulos MA
PLoS One; 2012; 7(6):e37946. PubMed ID: 22679488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
